alpha-synuclein nanobodies

Alpha-synuclein nanobodies are single-domain antibody fragments (VHHs) engineered to target and neutralize pathological aggregates of alpha-synuclein, a protein whose misfolding and accumulation into toxic oligomers and amyloid fibrils are central to the pathogenesis of Parkinson's disease and other synucleinopathies. Developed by institutions such as the Autonomous University of Barcelona, these nanobodies are designed—often utilizing deep-learning computational methods—to bind specific structural epitopes, such as the N-terminal region that orchestrates the transition from oligomers to fibrils. By arresting toxic oligomeric species and blocking their conversion into mature fibrils, alpha-synuclein nanobodies aim to prevent neurotoxicity and inhibit the prion-like spreading of pathology within the brain, offering promising therapeutic and diagnostic strategies.

Other names

alpha-synuclein nanobodyanti-alpha-synuclein nanobodiesanti-alpha-synuclein nanobodyanti-aS nanobodiesanti-aS nanobody